导师风采
邢镨元
个人信息
Personal Information
- 性别：女
- 导师类型：硕士生导师
- 职称：主任医师
- 该职称任职时间：20220901
联系方式
Contact Information
- 所属院系：肿瘤医院
- 所属专业：肿瘤学
- 邮箱 : xingpuyuan@cicams.ac.cn
- 工作电话 : 87788293
个人简介
Personal Profile
在肿瘤内科临床工作中个人亚专业为胸部肿瘤，尤其擅长肺癌的化疗、靶向治疗、免疫治疗，致力于精准检测指导下的肺癌个体化治疗。主要出诊单元为内科专家门诊、 胸内专家门诊、内科化疗门诊及互联网医疗门诊，接诊患者以胸部肿瘤内科治疗患者。完成临床工作同时，承担多项抗肿瘤新药临床研究工作（I期-III期，国内/国际多中心研究），以及研究者发起的临床研究，共计50余项，将临床与科研紧密结合，成果相互转化应用。
团队简介
Team Profile
待补充更新
- 研究方向Research Directions
肺癌靶向治疗,肺癌免疫治疗,生物标志物探索,抗肿瘤新药临床研究
- 在校研究生Current Graduate Students
硕士研究生 2 名，博士研究生 0 名
- 科研项目Research Projects
| # | 项目名称 | 起止日期 | 金额 | 项目类型 | 本人角色 |
|---|---|---|---|---|---|
| 1 | MDM2调控肺腺癌转移及EGFR-TKIs耐药机制研究 | 2022-12 —— 2024-12 | 20万元 | 主持的企业/行业委托重大项目 | 主持人 |
| 2 | 血管生成调控因子异常与肺癌ALK-TKI耐药关系的机制研究 | 2022-01 —— 2025-12 | 114万元 | 参与在研的国家或省部级科研项目 | 参与者 |
| 3 | 肺腺癌PSMB8甲基化调控机制及对免疫应答影响的探索性研究 | 2022-08 —— 2025-08 | 20万元 | 主持的企业/行业委托重大项目 | 主持人 |
- 发表论文Papers
| # | 论文题目 | 期刊名称 | 发表年份 | 论文署名 |
|---|---|---|---|---|
| 1 | Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma | Thorac Cancer | 2021-10 | 通讯作者 |
| 2 | Impact of crizotinib on long-term survival of ALK-positive advanced Non-small-cell lung cancer: A Chinese multicenter cohort study. | Chinese Journal of Cancer Research | 2019-06 | 第一作者 |
| 3 | Co-mutational assessment of circulating tumor DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer | JOURNAL OF CELLULAR AND MOLECULAR MEDICINE | 2019-10 | 第一作者 |
| 4 | The clinical significance of RET gene fusion among Chinese patients with lung cancer | Translational Cancer Research | 2020-10 | 第一作者 |
| 5 | What are the clinical symptoms and physical signs for non‐small cell lung cancer before diagnosis is made? A nation‐wide multicenter 10‐year retrospective study in China | Cancer Medicine | 2019-07 | 第一作者 |
| 6 | Data from real world to evaluate the effcacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis | Clinical and Translational Oncology | 2019-10 | 第一作者 |
| 7 | Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study | Journal of Cancer Research and Clinical Oncology | 2022-11 | 通讯作者 |
| 8 | Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations | Thoracic Cancer | 2021-11 | 通讯作者 |
| 9 | Real world study of the continuation of bevacizumab beyond disease progression afterfirst-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer | Thoracic Cancer | 2018-12 | 第一作者 |
| 10 | Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO IPI: a systematic review and meta-analysis | Journal for ImmunoTherapy of Cancer | 2019-12 | 第一作者 |
| 11 | Intracranial efficacy of alectinib in ALKpositive NSCLC patients with CNS metastases—a multicenter retrospective study | BMC Medicine | 2022-01 | 第一作者 |
| 12 | Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer | Thoracic Cancer | 2018-07 | 第一作者 |
| 13 | ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China | Thoracic Cancer | 2022-02 | 通讯作者 |
| 14 | ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer | Molecular Medicine | 2021-10 | 通讯作者 |
| 15 | Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation | Thoracic Cancer | 2021-08 | 通讯作者 |
| 16 | Changes and Influential Factors of Chemotherapy Usage for Non-Small Cell Lung Cancer Patients in China: A Multicenter 10-Year (2005-2014) Retrospective Study | Cancer Management and Research | 2020-07 | 第一作者 |
| 17 | Study protocol: A single‐arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first‐line immunotherapy | Thorac Cancer | 2021-10 | 第一作者 |
| 18 | YAP1 protein expression has variant prognostic significance in small cell lung cancer (SCLC) stratified by histological subtypes | Lung Cancer | 2021-10 | 通讯作者 |
| 19 | Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC) | Thoracic Cancer | 2021-09 | 通讯作者 |
| 20 | Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China. | Targeted Oncology | 2019-06 | 第一作者 |
| 21 | Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in？EGFR-Mutant Lung Adenocarcinoma | Frontiers in Oncology | 2021-05 | 通讯作者 |
| 22 | Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib. | Targeted Oncology | 2019-04 | 通讯作者 |
| 23 | Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor ( EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients | Cancer Manag Res | 2022-03 | 通讯作者 |
| 24 | 驱动基因阳性肺腺癌在靶向治疗中病理类型转化的机制与治疗策略 | 中国肺癌杂志 | 2020-08 | 通讯作者 |
| 25 | Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD) | Translational Lung Cancer Research | 2020-12 | 通讯作者 |
| 26 | 解析PD-1/PD-L1抑制剂分子结构差异与不良反应的相关性 | 中国肺癌杂志 | 2020-07 | 通讯作者 |
| 27 | Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer | BMC IMMUNOLOGY | 2018-04 | 第一作者 |
| 28 | 221 例 IIIA/N2期非小细胞肺癌患者的预后因素分析 | 癌症进展 | 2019-09 | 通讯作者 |
| 29 | Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small lung cancer | Frontiers in Oncology | 2020-04 | 通讯作者 |
| 30 | Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non small Cell Lung Cancer Failing Treatment with Osimertinib | Targeted Oncology | 2019-06 | 通讯作者 |
| 31 | Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis | Evid Based Complement Alternat Med | 2021-12 | 通讯作者 |
| 32 | Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen | Journal of Cancer | 2020-09 | 通讯作者 |
| 33 | Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK NSCLC: A multicenter retrospective analysis in China | Thorac Cancer | 2022-01 | 通讯作者 |
| 34 | Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study | ESMO Open | 2022-06 | 第一作者 |
| 35 | A real‐world study of dacomitinib in later‐line settings for advanced non‐small cell lung cancer patients harboring EGFR mutations | Cancer Med | 2022-02 | 通讯作者 |
| 36 | Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy. | BMC Cancer | 2023-03 | 通讯作者 |
| 37 | Low TP53 variant allele frequency as a biomarker for anti-programmed death (ligand) 1 monotherapy in lung adenocarcinoma | Cancer | 2023-12 | 通讯作者 |
| 38 | Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency | Cell Communication and Signaling | 2023-03 | 通讯作者 |
| 39 | Multi-dimensional characterization of immunological profiles in small cell lung cancer uncovers clinically relevant immune subtypes with distinct prognoses and therapeutic vulnerabilities | PHARMACOLOGICAL RESEARCH | 2023-08 | 通讯作者 |
| 40 | Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC | MOLECULAR CANCER RESEARCH | 2023-04 | 通讯作者 |
| 41 | Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort | Translational Lung Cancer Research | 2022-12 | 通讯作者 |
| 42 | Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study | BMC Medicine | 2022-11 | 第一作者 |
| 43 | Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma | Epigenomics | 2022-11 | 通讯作者 |
| 44 | Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis | Frontiers in Oncology | 2022-11 | 第一作者 |
| 45 | Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA | Thoracic Cancer | 2022-08 | 通讯作者 |
| 46 | ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production | Cell Communication and Signaling | 2022-10 | 通讯作者 |
| 47 | Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression | Cancer Management and Research | 2022-06 | 通讯作者 |
| 48 | Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients withNon‐Small Cell Lung Cancer Carrying Uncommon EGFR Mutations:A Comparative Cohort Study in China (AFANDA Study) | cancers | 2022-10 | 通讯作者 |
| 49 | Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases | Thoracic Cancer | 2021-12 | 通讯作者 |
- 科研获奖Research Awards
无
- 研究成果Research Findings
| # | 成果类型 | 项目/专利/新品种名称 |
|---|---|---|
| 1 | 出版高水平专著 | 肿瘤化疗患者症状管理 |
| 2 | 出版高水平专著 | 肿瘤内科原理与实践 |
| 3 | 作为主创人员获得授权的发明专利和新品种 | 预测肺腺癌患者小细胞转化风险的模型及其建立方法 |
| 4 | 作为主创人员获得授权的发明专利和新品种 | 预测小细胞转化的肺腺癌患者预后模型及其建立方法 |
| 5 | 作为主创人员获得授权的发明专利和新品种 | 预测小细胞转化肺腺癌患者转化速度的模型及其构建方法 |
| 6 | 出版高水平专著 | 临床肿瘤内科手册 |